Hypoxia News and Research

RSS

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.

TLR4 may provide new strategy for treating patients with PDAC: Study

Pancreatic ductal adenocarcinoma is a highly malignant digestive tumor with a very poor prognosis. Hypoxia-inducible transcription factor-1α is involved in malignant progression in many solid tumors, including PDAC, upregulation of HIF-1α accelerates PDAC progression, but the exact regulatory mechanisms of HIF-1αin PDAC has not been unequivocally addressed.

28 Jun 2010

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

Pulmonary arterial hypertension (PAH) is a progressive disease, marked by shortness of breath and fatigue which can be fatal if untreated. Increased pressure in the pulmonary artery and its branches is associated with dysfunctional growth control of endothelial and smooth muscle cells leading to excessive thickening of the blood vessel wall, obliteration of the lumen and right heart failure.

22 Jun 2010

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.

21 Jun 2010

Symposium explores new understanding of mitochondrial function, cellular bioenergetics in cancer research

Seahorse Bioscience, Inc., the leader in instruments for assessing cellular bioenergetics, recently organized a symposium on Cancer and Mitochondrial Function featuring Douglas Green, Ph.D., from St. Jude Children's Hospital; Navdeep S. Chandel, Ph.D., from Northwestern Medical School; and Nicholas C. Denko, Ph.D., from Stanford University School of Medicine.

17 Jun 2010

Researchers establish link between air pollution and SDB

Researchers from Brigham and Women's Hospital and the Harvard School of Public Health have established the first link between air pollution and sleep-disordered breathing, a known cause of cardiovascular diseases.

15 Jun 2010

RCSI scientists make breakthrough in understanding human adaptation to high altitude environments

A group of top international scientists including geneticists from the Royal College of Surgeons in Ireland has made a breakthrough in understanding human adaptation to high altitude environments.

9 Jun 2010

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

Threshold Pharmaceuticals, Inc. today announced results from Phase 1/2 clinical trials in various solid tumors related to its hypoxia-activated prodrug, TH-302. The results were presented during the American Society for Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.

8 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

High oxygen delivery after postcardiac arrest leads to higher rate of death in hospitals

Patients who have excessive oxygen levels in arterial blood (hyperoxia) following resuscitation from cardiac arrest have a higher rate of death in the hospital than similar patients without arterial hyperoxia, according to a study in the June 2 issue of JAMA.

2 Jun 2010

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Dendreon Corporation today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.

1 Jun 2010

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.

25 May 2010

New FDA approved Landon Medical LM-800 Finger Pulse Oximeter available for home use

PulseOximetersDIRECT.com, the leading online retailer of portable Pulse Oximeter products introduces today the new, affordable $39 FDA approved Landon Medical LM-800 Finger Pulse Oximeter for home use.

24 May 2010

New clinical procedures, better diagnostics improve prognosis for children born with severe acute asphyxia

The prognosis for children born with severe acute asphyxia has improved in recent years owing to new clinical procedures and better diagnostics, according to a new doctoral thesis from the Swedish medical university Karolinska Institutet. By measuring levels of lactic acid in the blood during childbirth and the brain activity of the newborn afterwards, doctors can make a much more reliable assessment of the risk of serious brain damage.

21 May 2010

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Exelixis, Inc. today reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma (GB), the most common and aggressive form of brain cancer. Dr. Patrick Wen from the Dana Farber Cancer Institute in Boston, MA will present the data in an Oral Session (Abstract #2006) on Saturday, June 5 at 5:00 p.m. at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.

21 May 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Exelixis, Inc. today reported long-term results in a cohort of 37 medullary thyroid cancer (MTC) patients who participated in the phase 1 study of XL184. Dr. Razelle Kurzrock from the MD Anderson Cancer Center in Houston, TX will present the data in a Clinical Science Symposium (Abstract #5502) on Monday, June 7 at 10:15 AM at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

Gene therapy shows positive effects in rat models of PAH: Researchers

Gene therapy has been shown to have positive effects in rat models of pulmonary arterial hypertension, according to researchers at the University of Adelaide in Australia.

20 May 2010

Sleep apnea increases insulin resistance: Study

Sleep apnea may cause metabolic changes that increase insulin resistance, according to researchers from the University of Pittsburgh Medical Center. The intermittent hypoxia associated with sleep apnea causes a distinct drop in insulin sensitivity in mice, even though chronic hypoxia, such as that associated with high altitude, did not.

18 May 2010

FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis

FibroGen, Inc. today announced that administration of investigational therapy FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), reversed the process of fibrosis in a preclinical model of radiation-induced lung fibrosis, a finding that has implications for treating multiple types of fibrotic disease.

18 May 2010

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

SNM's Molecular Imaging Center of Excellence wrapped up its Molecular Neuroimaging Symposium today in Bethesda, Md., at the Natcher Auditorium of the National Institutes of Health (NIH).

10 May 2010

Hypoxia News and Research

Further Reading

TLR4 may provide new strategy for treating patients with PDAC: Study

Elevation of Smurf1 may play a role in molecular basis of PAH: Study

Exelixis announces regaining of rights to develop and commercialize XL184

Symposium explores new understanding of mitochondrial function, cellular bioenergetics in cancer research

Researchers establish link between air pollution and SDB

RCSI scientists make breakthrough in understanding human adaptation to high altitude environments

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

High oxygen delivery after postcardiac arrest leads to higher rate of death in hospitals

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

New FDA approved Landon Medical LM-800 Finger Pulse Oximeter available for home use

New clinical procedures, better diagnostics improve prognosis for children born with severe acute asphyxia

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Gene therapy shows positive effects in rat models of PAH: Researchers

Sleep apnea increases insulin resistance: Study

FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

E-Cigarettes and Ethanol: A forensic Perspective on Vaping

Understanding Consumer-Consented Data to Optimize Digital Health Programs

The Future is Wearable: Advancing Human Health Through Portable Spectroscopy

Latest News